Astrana HealthASTH +2.37%87 Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.34 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 583 Healthcare Providers & Services companies, Astrana Health ranks better than 99.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Astrana Health's annualized net income for the quarter that ended in Mar. 2026 was $58 Mil. Astrana Health's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-344 Mil. Therefore, Astrana Health's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was Negative Tangible Equity%.
The historical rank and industry rank for Astrana Health's Return-on-Tangible-Equity or its related term are showing as below:
ASTH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 19.66 Med: 27.51 Max: 111.41
Current: Negative Tangible Equity
During the past 13 years, Astrana Health's highest Return-on-Tangible-Equity was 111.41%. The lowest was 19.66%. And the median was 27.51%.
ASTH's Return-on-Tangible-Equity is ranked better than 99.83% of 583
companies
in the Healthcare Providers & Services industry
Industry Median: 9.74
vs ASTH: Negative Tangible Equity
Astrana Health (NAS:ASTH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Astrana Health Return-on-Tangible-Equity Related Terms
Astrana Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Astrana Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASTH vs MD, SGRY, ADUS: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Astrana Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Astrana Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Astrana Health (ASTH) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Astrana Health and its competitors. Over the past decade, Astrana Health's Return-on-Tangible-Equity has ranged from 19.66 to 111.41. According to the industry distribution chart, Astrana Health ranks #1 out of 583 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is Astrana Health's Return-on-Tangible-Equity too high?
Astrana Health's current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 19.66 to a high of 111.41. Based on the distribution chart, Astrana Health ranks #1 out of 583 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's Return-on-Tangible-Equity compare to MD and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #1 out of 583 companies for Return-on-Tangible-Equity. This places Astrana Health in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 9.74. Historically, Astrana Health's own Return-on-Tangible-Equity has ranged from 19.66 to 111.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.74, based on 583 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.34, compared to a current price of $44.43 — trading 46% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Astrana Health (ASTH), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $44.43 is trading 46% below its estimated GF Value™ of $82.34.
GuruFocus considers Astrana Health to be Significantly Undervalued.
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
